And I'd be remiss if I didn't mention the upcoming basket trial for posi in EGFR and HER2 exon 20 insertion mutations in multiple tumor types where it may be found as another pick me upper to share price. Per Dr Heymach's recent video that would double the # patients that would be treated with pozi to some 40,000.
I have to correct my post regarding a very very preliminary abstract.
I thought it may have come out at the end of June last year since somewhere I saw (imagined? Yes, what I saw I think was a date to a workshop) that the Journal reference was dated June. Since this abstract is correlated to WCLC in Sept which is 3 weeks earlier than last year starting on Sept 23rd, I would have thunk that the very very preliminary abstract would be available (think of it as a placeholder abstract) but nothing available yet. The reason I bring this up now is that I was just reading an Investopedia article that came out today titled “Top 4 Small-Cap Stocks for 2018” that discusses SPPI.
Investipedia stated i.e. “The stock price soared again at the end of September 2017 on news that lung cancer drug poziotinib showed success in early clinical trials” which coincided w the PR/abstract release around Sept 5th and “More positive news on the drug sent the stock even higher in October” coincided with the CC during the conference. Anyhows, the fireworks will start 3 weeks earlier than last year, around Sept 5th (release of abstracts), as opposed to the end of Sept. There was a rise from $7.33 on Aug 3rd to $8.96 on Aug 4th last year. I suspect this is when the preliminary abstract came out but can’t be sure of it since I didn’t find out about the preliminary abstract till towards the end of Sept last year (but I'll be paying attention this year). So, I stand corrected. This very very preliminary abstract I would expect to see towards the end of July, perhaps August with the full abstract available Sept 5th (w SPPI PR noting it), and CC update during WCLC around Sept 24th.